Keynote: The Natural Biologic LNFPIII as Therapeutic for Inflammation Based Diseases
Start Date
10-5-2016 12:00 PM
End Date
10-5-2016 1:00 PM
Description
Dr. Harn is Professor, Georgia Research Alliance Distinguished Investigator, the Director of Infectious Diseases, UGA, and the Associate Director of the Center for Vaccines and Immunology at UGA. He has performed research in biochemistry, vaccine design and development and immune regulation for over 30 years. Dr. Harn spent the majority of his research career at Harvard Medical School and the Harvard School of Public Health. He moved to the University of Georgia in 2009 where he is Georgia Research Alliance Distinguished Investigator in Vaccines. In immune regulation he studies how helminth parasites bias host immune systems. His lab identified first immune modulatory sugar from helminthes, Lewisx. Interestingly, Lewisx is also part of the structure of the human milk oligosaccharide LNFPIII. Working with collaborators they demonstrated that nanomolar amounts of LNFPIII conjugates activate innate immune cells and drive anti-inflammatory responses in vivo. Dr. Harn has prepared monoclonal antibodies to surface antigens of Schistosoma mansoni, and defined two vaccine candidates which are in clinical intervention trials in China and the Philippines.
Keynote: The Natural Biologic LNFPIII as Therapeutic for Inflammation Based Diseases
Dr. Harn is Professor, Georgia Research Alliance Distinguished Investigator, the Director of Infectious Diseases, UGA, and the Associate Director of the Center for Vaccines and Immunology at UGA. He has performed research in biochemistry, vaccine design and development and immune regulation for over 30 years. Dr. Harn spent the majority of his research career at Harvard Medical School and the Harvard School of Public Health. He moved to the University of Georgia in 2009 where he is Georgia Research Alliance Distinguished Investigator in Vaccines. In immune regulation he studies how helminth parasites bias host immune systems. His lab identified first immune modulatory sugar from helminthes, Lewisx. Interestingly, Lewisx is also part of the structure of the human milk oligosaccharide LNFPIII. Working with collaborators they demonstrated that nanomolar amounts of LNFPIII conjugates activate innate immune cells and drive anti-inflammatory responses in vivo. Dr. Harn has prepared monoclonal antibodies to surface antigens of Schistosoma mansoni, and defined two vaccine candidates which are in clinical intervention trials in China and the Philippines.